Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Combined Modality Therapy

Known as: Treatment, Multimodal, concurrent therapy, Therapies, Combined Modality 
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY… Expand
National Institutes of Health

Related topics

Related topics

7 relations
Antineoplastic Combined Chemotherapy Protocolsinterdisciplinary collaborationnursing therapystandards characteristics

Narrower (2)

Combination Drug Therapycombination cancer therapy

Broader (1)

Therapeutic procedure

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
BACKGROUND In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Highly Cited
2013
Highly Cited
2013
Nivolumab plus ipilimumab in advanced melanoma.
BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4… Expand
  • table 1
  • figure 1
  • figure 2
Highly Cited
2010
Highly Cited
2010
Infliximab, azathioprine, or combination therapy for Crohn's disease.
BACKGROUND The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease… Expand
  • table 1
  • figure 1
  • table 2
  • table 2
  • figure 2
Review
2006
Review
2006
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
BACKGROUND Lapatinib, a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 (HER2, also referred to as… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2003
Highly Cited
2003
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
BACKGROUND Imatinib, a selective inhibitor of the BCR-ABL tyrosine kinase, produces high response rates in patients with chronic… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Highly Cited
2003
Highly Cited
2003
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.
BACKGROUND Despite aggressive local therapy, patients with locally advanced bladder cancer are at significant risk for metastases… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Highly Cited
1999
Highly Cited
1999
Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
Combination therapy for HIV-1 infection can reduce plasma virus to undetectable levels, indicating that prolonged treatment might… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
1998
Highly Cited
1998
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
BACKGROUND AND METHODS National surveillance data show recent, marked reductions in morbidity and mortality associated with the… Expand
Highly Cited
1998
Highly Cited
1998
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.
BACKGROUND Only 15 to 20 percent of patients with chronic hepatitis C have a sustained virologic response to interferon therapy… Expand
Highly Cited
1996
Highly Cited
1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
BACKGROUND Uncontrolled studies suggest that a combination of chemotherapy and radiotherapy improves the survival of patients… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE